Omnicell, Inc.

Omnicell, Inc., a for-profit manufacturer of pharmacy automation and medication management solutions headquartered in Cranberry Township, Pennsylvania, operates exclusively as a prime contractor supplying automated medication dispensing cabinets, point-of-use medication systems, workflow management software, controlled substance management solutions, and maintenance and support services to federal healthcare agencies. The company competes full-and-open with no SBA set-aside certifications and has generated $3.63 billion in combined potential value across 5,232 prime awards since 1998, with $919.8 million in obligations as of the source snapshot.

Omnicell's federal customer base concentrates heavily in the Department of Veterans Affairs. The top five funding customers by potential value account for 79% of combined dollars and anchor the portfolio: VA VISN 12 (59 awards, $1.2 billion), VA VISN 20 (279 awards, $786.7 million), VA VISN 22 (442 awards, $618.8 million), VA VISN 17 (223 awards, $134.6 million), and VA VISN 5 (141 awards, $117.5 million). By award count, VISN 22 dominates with 442 awards across all segments; VISN 10 and VISN 6 contribute 306 and 289 awards respectively. Outside the VA, the Army Medical Command placed 307 awards valued at $48.8 million, and Omnicell serves the Defense Health Agency, Indian Health Service, National Institutes of Health Clinical Center, and 52 other federal agencies in smaller volumes. The concentration is extreme — a single VA VISN (VISN 12) represents 33% of all potential dollars despite 31% coverage of award count, signaling a mix of high-value equipment procurements and high-ceiling vehicles in that network.

Omnicell's federal vehicle position is dominated by the GSA Medical Equipment and Supplies Federal Supply Schedule (FSS-65-II-A), under which 3,144 task orders carry $2.1 billion in combined potential value. The vendor also holds multiple single-award blanket purchase agreements with individual VISNs: a $35 million BPA with VISN 5 (awarded June 30, 2025, expiring June 29, 2030), a $3.3 million BPA with VISN 5 (awarded October 1, 2025, expiring September 30, 2028), and a $2.4 million single-award IDIQ with VISN 23 (awarded May 1, 2026, expiring April 30, 2029) for pharmacy automation maintenance services. Task orders under these vehicles fund delivery of equipment, software subscriptions, installation, warranties, and ongoing maintenance. The FSS schedule serves as the primary vehicle generating the majority of Omnicell's task order volume across all VISNs.

Activity has remained relatively stable year over year — 168 awards in 2022, 193 in 2023, 154 in 2024, 154 in 2025, and 97 through late September 2026. A recompete cliff is present: 161 awards with ultimate completion within the next twenty-four months carry combined potential value of $67.4 million, representing near-term exposure to competitive renewal or loss, particularly within maintenance service contracts and periodic equipment procurement cycles across VISN networks.

Omnicell's work portfolio splits across medical equipment procurement (4,543 awards under NAICS 339112, Surgical and Medical Instrument Manufacturing) and maintenance services (1,025 awards under PSC J065, Maint/Repair/Rebuild of Medical Equipment). Representative recent work includes a $3.7 million sole-source purchase order from VISN 6 (Durham VA Medical Center) for XT Medication Cabinets and anesthesia workstations (awarded September 28, 2026); a $4 million sole-source purchase order from VISN 17 for XR2 robotic medication dispensing and packaging system with robotic resident expert support running through September 2, 2032 (awarded September 3, 2026); a $4.9 million BPA call from VISN 20 for point-of-use medication cabinets and services (awarded October 28, 2025); and a $1.3 million purchase order from VISN 19 for an Omnicell cabinet upgrade (awarded September 30, 2025). Maintenance and service calls typically range from $15,000 to $500,000 and cover on-site support, preventative maintenance, software updates, staff training, and parts replacement across individual VA medical centers and community-based outpatient clinics.

Service Contract Inventory data shows minimal reporting: SCI captured 95 prime records and 3 sub records across FY2022–FY2025, with zero invoiced revenue reported in SCI for any fiscal year. The FTE trajectory shows near-zero staffing in SCI-reportable service contracts (0.6 FTEs recorded in FY2025 across 27 prime and 3 sub records), indicating that SCI-reportable services represent a negligible share of Omnicell's federal revenue and workforce. Omnicell's federal business is predominantly goods procurement (equipment, cabinets, and hardware) with embedded services rather than standalone service contracts above the SCI threshold.

The company operates through subsidiary brands. Pandora Data Systems, Inc. and Aesynt Incorporated (a for-profit goods manufacturer) provide product portfolio depth and specialization; these subsidiaries' capabilities are reflected in named award descriptions such as "Omnicell Pandora Maintenance and License" contracts and Aesynt-branded equipment offerings. No SBA certifications (8(a), HUBZone, SDVOSB, WOSB, etc.) are held; Omnicell competes as a large, uncertified prime contractor. The vendor does not subcontract to other primes; it operates exclusively as a prime and does not appear as a named subcontractor in the federal contract landscape within this source.